| Previous Close | 1.6800 |
| Open | 1.7600 |
| Bid | 1.68 x 2200 |
| Ask | 1.69 x 2900 |
| Day's Range | 1.5610 - 1.7500 |
| 52 Week Range | 1.3600 - 15.0000 |
| Volume | 1,348,137 |
| Avg. Volume | 856,834 |
| Market Cap | 77.942M |
| Beta (3Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Arcadia Biosciences and Achaogen were two winners in the biotech arena on Monday. Achaogen soared over 20% on positive clearance news for the Thermo Scientific QMS Plazomicin Immunoassay. There was no remarkable news from Arcadia Biosciences to explain the jump.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) has provided clearance for the Thermo Scientific QMS Plazomicin Immunoassay that provides a quantitative measure of plazomicin in human plasma using automated clinical chemistry analyzers. Results of the assay will be used to assist in the management of patients receiving plazomicin therapy. Plazomicin, marketed as ZEMDRI™ in the United States, was approved by the U.S. Food and Drug Administration for the treatment of adults with complicated urinary tract infections, including pyelonephritis, due to certain Enterobacteriaceae.
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.
-- Company provides update on ZEMDRITM commercialization and launch -- -- Conference call today at 8:30 a.m. Eastern Time -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 --.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has begun a review of strategic alternatives to maximize shareholder value, including but not limited to the potential sale or merger of the Company or its assets. The Company also announced a restructuring of its organization to preserve cash resources which is expected to reduce operating expenses by approximately 35-40 percent, excluding one-time charges. “We are committed to evaluating strategic alternatives that enhance value for shareholders while maintaining our focus on the successful launch of ZEMDRI and the development of C-Scape as well as aggressively managing our operating expenses," said Blake Wise, CEO of Achaogen.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
-- MAA submission for complicated urinary tract infections (cUTI), bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterial.
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials addressing multi-drug resistant gram-negative ...
--Company presentation scheduled for October 2, 2018 at 1:40 p.m. EDT--. SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To ...
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Shares of Achaogen were plummeting in Tuesday trading after the FDA cleared the way for its Zemdri as a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae but issued a complete response letter for the drug as a potential treatment option for blood stream infection. Shares of Avinger were soaring after the company announced a positive initial case experience using the company's next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).